The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 02, 2022

Filed:

Apr. 27, 2018
Applicants:

City of Hope, Duarte, CA (US);

California Institute of Technology, Pasadena, CA (US);

Inventors:

Javier Gordon Ogembo, San Dimas, CA (US);

Lorraine Zvichapera Mutsvunguma, Duarte, CA (US);

Alison Evelynn Ondrus, Pasadena, CA (US);

Assignees:

CITY OF HOPE, Duarte, CA (US);

CALIFORNIA INSTITUTE OF TECHNOLOGY, Pasadena, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/08 (2006.01); A61K 47/68 (2017.01); A61K 47/65 (2017.01); A61K 35/763 (2015.01); A61K 38/16 (2006.01); A61K 39/245 (2006.01); A61K 39/42 (2006.01);
U.S. Cl.
CPC ...
C07K 16/085 (2013.01); A61K 35/763 (2013.01); A61K 38/162 (2013.01); A61K 39/245 (2013.01); A61K 47/65 (2017.08); A61K 47/6811 (2017.08); A61K 47/6839 (2017.08); A61K 39/42 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C12N 2710/16222 (2013.01);
Abstract

Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more epitopes of EBV gp350 and neutralize EBV infection. Also disclosed are immunogenic peptides comprising one or more gp350 epitopes, EBV antibody-small molecule conjugates and pharmaceutical compositions comprising the antibody or an immunogenic fragment thereof, one or more epitopes of EBV gp350, one or more immunogenic peptides, or the EBV antibody-small molecule conjugate. The antibodies, epitopes, immunogenic peptides, conjugates, and pharmaceutical compositions can be used to treat or prevent EBV infections and EBV-associated conditions and diseases.


Find Patent Forward Citations

Loading…